Yoshitomo Hamuro

ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders. Many of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases.